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ABSTRACT
Objective:
To test the null hypothesis that misoprostol, an oral prostaglandin EI analog. is not worse
than oxytocin intravenous bolus in minimizing blood loss in the third stage of labour.
Method:
One hundred and fifty-six women, having vaginal delivery and at low risk of postpanurn
hemorrhage, were stratified by oxytocin use in labour and randomly assigned to receive
either misoprostol 200~g orally with the anterior shoulder. or oxytocin intravenous bolus
after placental delivery. the standard at our institution. Sample size was calculated using a
one-tailed a=O.05 and a power of 80%, with change in pre-dclivery to 1st day postpanum
hematocrit as the primary outcome.
Re:sults:
Baseline demographic data were similar. There was no significant difference in the change
in hematocrit between the misoprostol (0.046% packed cell volume[PCVJ) and the oxytocin
(0.048% PCV) groups (P=O.49). More women in the oxytocin stratum received addition3!
oxytocin postpartum (P=O.OO2). There were no differences in the frequency of clinical
estimate of postpanum blood loss greater than 500mL. use of other uterotonic agems, manual
removal of placenta, dilation and curreUage, transfusion, gastrointestinal side effects, or
maternal satisfaction. There were no differences in frequency of maternal fever postPIlI1Ulll.
After delivery, more women in the misoprostol group strongly preferred to have a medication
in the fonn of a pill. rather than an intrnvenous injection. .at the time of delivery ofthdr baby
(82.8% versus 42.2%. P<O.OOOOI. Mann WhilllCy lest)
Conclusions:
Oral misoprostol is a safe and efToctive option 10 minimize blood loss in the third stage of
labour. for women allow risk of JXlStparturn hemorrhage.
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Chapter 1: INTRODUCTION
Postpartum hemorrhage refers to excessive blood loss after delivery. Early
postpartum hemorrhage occurs within thc first 24 hours after birth, and has classically
been defined as an estimated blood toss of 500mL or greater in this time period (I).
Hemorrhage, infcction, and hypertension form the "lethal triad" of obstetrics, being
collectively responsible for the majority of direct obstctric matcrnal deaths (2).
Early postpartum hemorrhage has a limited number of etiologics, including lower
genital tract lacerations, retained products of conception and abnormalities of
placentation, uterine rupture or inversion, and coagulopathy. However, the most
common cause of early postpartum hemorrhage is uterine atony (I).
Patients who have had a previous postpartum hemorrhage due to atony have a
recurrence risk of 25% (3). There are other risk factors for PPH (Appendix A).
However, most women who have PPH have no identifiable risk factors, so, this
potentially catastrophic complication can occur with little or no warning. Therefore,
algorithms for managcment of PPH have been developed (Figure 1.IX4). If conservative
management fails, operative intervention. pelvic vessel embolization or ligation, and
hysterectomy may be necessary.
Figure!.1 MANAGEMENT 0.' POSTPARTUM HEMORRHAGE
This management should be inslinctive following logical sleps,
Algorithm
Assess Maternal A.B.C.'s
Maternal Resuscitation
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•Manually Remove Placenla
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I Bleeding Slopped I
,. I Bleeding Slopped I
IBI"di"',C,"'i""," /
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•Hemabate
Inlramyomelrial250mcg
Inlramuscular 250mcg
Do Not Give to Palients wilh Asthma
Ergonovine 0.2 mgm l.V. 30 seconds
LM.3 minules
Do nOI Give to the Hypertensive Patient
After placenta removed-as soon as you can see, inspect the cervix and vagina for lacerations.
Make sure they are sutured.
Chapter 2: BACKGROUND
2.1 Background
Globally, ht:l1lOfTtlage is still a main cause of maternal mortality. One third of
maternal deaths tbat occur from hemonhage are due (0 postpanum hemolThage (3). In
developed countries the incidence is in the r.tnge of 2-11% of deliveries (5). The
incidence can be much higher in developing countries. This difference is due, in pan, to
active versus physiologic management of the third stage of labour. Physiologic
management is the routine in developing countries. This involves avoidance of umbilical
cord clamping until placental delivery or if the cord is cut prior to placental delivery the
blood is allowed to drain from the placenta immediately. The woman assumes a posture
that will allow gravity to assist in placental delivery. She then pushes with uterine
contntctions to deliver the placenta. The baby is placed to the breast to cause II
physiologic release of oxytocin (5). Active management of the third stage generally
involves the prophylactic administration of a uterotonic agent once the anterior shoulder
is delivered or immediately after delivery. The umbilical cord is clamped within 30
seconds of delivery. Controlled cord tmction is applied once signs of placental separation
an: evident and uterine massage continues after placental delivery until blood loss begins
to decrease (I). Active management of the third SI3.ge reduces the incidence of
postpartum hemorrhage by 40% (5). Physiologic management is routine management of
the third stage in developing countries as oxytocics are unstable in wann temperatures
and refrigeration is not widely available. Most also require sterile equipment and trained
personnel for administration. The majority of women deliver at home where they may be
assisted by traditional birth attendants. without access 10 medical facilities.
In developed counlries. where maternal mortality rates are low. lhe degree of
medical intervention into the physiologic process of the third stage began to be
questioned TIle "'Bristol third stage trial" was carried out to detenninc if ocli\1:
management was justified in the controlled seuing of a British maternity hospital. One
thousand six hundred and nint:ty-five women were mndornly allocated to active ew
physiologic management of the third stage of labour with estimated blood loss of 500mL
or greater was the primary outcome measure. Although the sample size was calculated to
be 3900 women. the rale of postpartum hemorrhage was so much greater in the
physiologic group. 17.9% versus 5.9% in the active management group, that interim
analysis resulted in early tennination of the study (5).
In selecting a uterotonic agent effectiveness. safety. route of administration.
stability. and cost are all considerations. Ergot alkaloids were the first effective agents
used few the treatment of postpartum hemorrhage. thereby dramatically reducing maternal
mortality. Their onset of action is delayed for 4-5 minutes after administration. but their
effects last for several hours. They are vasoconstrictors. with side effects including
nausea. vomiting, headache. hypenension. and occasional repons of seizure. cardiac
arrest and cerebral hemorrhage (6). It is because of these side effects thm they are
relatively contra-indicated in patients with hypenension, and that other uterotonic agents
have been sought. Administration is parenteral or by an oral tablet. Ergometrine must be
refrigerated and protected from light. Thus improper storage can lead to loss of polency.
especially problematic in developing counties.
Oxytocin analogs were the next proven effective agcnts to be used. Administered
parenterally. the onset of action is as rapid as 30 seconds. but more transient. lntmvenous
oxytocin causes vasodilation. and side effects including hypotcnsion. nausea and
vomiting (7). A combination of these two medications is also used, Syntomctrine®.
administcred imramuscularly. consisting of oxytocin S units and Ergometrine O.Smg. to
yield a rapid onset. but prolonged duration of action. Side effects are hypenension and
its associated complications (8).
2.2 Prostaglandins
2.2.1 Prostaglandins in Obstetrics
Prostaglandins arc physiologic substances with widespread functions throughout
the body. Uke other eicosanoids. they are derived from arachadonic acid. Products of
the cydo-oxygenase pathway. prostaglandins' chemical structure is that of a SubsliMed
pentane ring with Iltlached fally acid moieties at twO adjacent carbons (Figure 1.2)(9).
Figure 1.2 STRUCfURE OF PROSTAGlANDINS OF THE F AA1> E SERIES AND
SOME ANALOGUES IN CURREl"Io'T USE
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Prostaglandins are named by kner classes (A. B. D. E and I) denoting differing stlllcture
of the pentane ring and numeric designation indicating the number of double bonds in the
fauy acid moieties (9). Production of prostaglandins is regulated by substrate
availability. dependent upon phospholipase mediated release of arachadonic acid release
from cell membmne Stores, and cydo-Qxygenase. also known as prostaglandin GlH
synthase. Metabolism is achieved by beta and omega oxidation of the fauy acid.
Receptors. present in the cell membrane and intracellular organelles. are specific for the
pentane ring and not the fauy acid structure. Therefore. synthetic products have been
produced which have similar effects but are resistant to metabolism (Figure 1.2X9).
Prostaglandins are intimately involved with boIh pregnancy maintenance and
labour and delivery. Found in the amniotic fluid. prostaglandin levels increase
approaching teoo and increase further with the onset of labour. Prostaglandin Flo: is
produced by the m.:nemal decidua and regulates myometrial activity. Action on the
myometrium is dependent upon the presence of prostaglandin receptors. of which there
are four isofonns. Two of these receptor isofonns promote uterine muscle relaxation and
two promote uterine muscle contraction (10).
Prostaglandin E2 is produced by the amnion aJXI plays a critical role in cervical
ripening. essential for labour progression. In the cervix. prostaglandin E2 causes
vasodilation and increased vascular penneability. This facilitates neutrophil invasion, the
source of collagenase. which causes collagen degradation and cervical softening (10).
Both prostaglandin E and F stimulate myometrial contractility and prostaglandin
receptors are present throughout gestation (9). 'Therefore. they have various applications
in obstetrics and gynecology as stimulants of uterine contraction. TIley have been
investigated in this capacity since the 1960's and have becOlne established agents for firsl
and second trimester pregnancy tennination. cervical ripening and induction of labour,
and treatmenl of postpartum hemorrlJage.
2.2.2 Prostaglandins and Postpartum Hemorrhage
Both proslaglandin E2 and Flu analogs have been investigaled in the lreatmenl of
refraclory poslpartum hemorrhage. Prostaglandin E2 has primarily been used as an
inlravenous infusion. Although effective. side effeclS include nausea. vomiting, dianhea,
ulerine hypenonus, tachycardia, increased slroke volume. and a decrease in peripheral
vascular resiSlance (II). occasionally kading 10 significant hypoiension (12). There have
also been occasional reports of severe hypertension (13) secondary to arlerial spasm.
Analogs of prostaglandin E2 have also been administered direclly 10 the ulerine cavity
via Foley calheler or suppository, although Ihis is uncommon.
Analogs of prostaglandin Flu have also been invesligaled. Routes of
adminiSlration include inlravenous. intramuscular. and intramyomemal. The IS-methyl
analog, Hemaba~, administered inlramuscularly. has been widely used. and has
become fronl line medical therapy for PPH. Hemabale is successful 85-95% of the time
(14). and its failure mosl often indicates a cause for hemorrhage other than uterine atony
(15). The rate of side effecls of nausea. vomiling and diarrhea is approximately 10%
(15). Other side effects include hypertension. headache. nushing. and a lfanSienl mild
hyperthennia (11). Hearl rate an<! cardiac output increase, but there is no change in
syslemic vascular resistance (16). A significant side effect of bronchospasm comm-
indicates ils use in aslhmatics. A less recognized complication of arlerial oxygen
desaluration in normal healthy women is not uncommOn. This is due both 10 an increase
in pulmonary vascular resistance and broncoosp.'LSmleading to pulmonary shunting (17).
Thus. prostaglandins previously used in obstetrics have potentially significant
morbidity. 1bey also require refrigeration or parenteral administration and are eJlpcnsive.
At the commencement of this study. no trials invcsligating misoprostol for postpanum
hemorrhage prevenlion h3d been reponed. Seven lrials were published describing lhe
prophylactic use of a prostaglandin in the lhird stage (18-24). Five studies invesligated a
proslaglandin Fla analog and two slUdied a prostaglandin E2 derivative. Three of these
sludies had small sample sizes (19-21). one amalgamaled randomized and non-
randomized study groups (22) and another had no sample size calculation with a result of
no significant difference between treatment and control groups (24). All studies found
the prostaglandin 10 be as effective. if not more effeclive lhtln Ihe slandard uterolonic to
which it was compared.
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2.2.3 Misoprostol
Misoprostol (Cytotec. Searle) is a synthetic methyl ester of prostaglandin El with
a proven uterotonic effect in controlled studies, including published data from our own
center (25). It is marketed for prevention and treatment of NSAlD induced gastric and
duodenal ulcers at a dose of 800~g per day. Its uterine effect is mediated by selective
binding 10 EP2IEP3 prostanoid receptors (26) It is rapidly absorbed after oral
administration, detectable in the circulation within two minutes, with a Tmax of thiny
minutes. Misoprostol is rapidly metaOOlized. by most body tissues, inlO inactive
metaoolites, and therefore not contra-indicaled in patients with hepatic or renal
dysfunction, although caution is still advised in the product monograph. Other cautions
are based primarily on repons of injectable prostaglandins and relate to epilepsy and
cardiovascular conditions where hypotension may pose a specific problem, such as
coronary artery disease. Primary reponed side effects of misoprostol are diarrhea,
nausea. and abdominal discomfort. These appear to be dose dependent.
2.2.4 Misoprostol and Postpartum Hemorrhage Publications
Since this study began. there have been other investigations published of
misoproslol use in the prevention of poslpaItum hemorrhage. El·Refaey et aI. published
two prospective observational reports of 6ClOJ1g of orol misoproslOl given after umbilical
cord clamping (27. 28). In the initial report on 100 women. six had and estimated blood
loss of greater than or equal to SOOmL None had an estimated blood loss of IOOOmL or
more. Subsequent to misoprostol, oxytocin was administered to six women and a blood
transfusion 10 one. They reported shivering to be a significant side effect, affecting sixty-
eight percent. The 6% riltc of postpartum hemorrhage was considered cOffipar:1blc to
historical results of Syntomctrine®. In the second repon by this group. 237 women were
observed. Estimaled blood loss greater than or equal to SOOmL was. once again, six
percent with no women having an estimated blood loss grealer than or equal to 10000L
Subsequent oxytocin was administered to 5%. lJ'anSfusion to two women and shivering
reported in 62%. 1bey also observed a O.5°e tempenuure increase after misoprostol
administration. 1bey concluded Wt the nue of postpanum hernorrlJage was bener than
that reported for physiologic management of the third stage and comparable to that
reported for Syntometrin~.
There have been two reports of randomized trials of rectal misoprostol, 400J.lg. for
postpartum hcmorrhage prevention (29.30). The first trial was a prospective. unblinded
comparison of misoprostol in 241 women with one ampoule of Syntometrine@.
intramuscularly, in 250. The primary outcome measure was estimated postpartum blood
loss of 500mL or greater. This study had problems with its randomization protocol.
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Women who developed hypenension in labour after allocation 10 Ihe Syntometrine@
group only. \\.'Cre excluded and the allocation 10 the Synlomelrine@ group reassigned 10
O(her participants. Afler analysis of the dala based upon the medication thai lhe women
aclually received. the dala was reanalyred after excluding all women in both groups with
hypenension in labour. a tOlal of 84. yielding "similar resuhs". With respect to the
primary outcome measure. infonnation was available 00 231 women in the misoproslol
group and 233 in Ihe Syntometrine@ group. The incidence of IXIstparturn hemorrhage
was low in both groups, 0.9% and 0.4% respectively. They found no difference in r:tles
of postpartum hemorrhage between groups. but concluded their sample size was
insufficient for this comparison. In the second study by this group, 400jlg of reclal
misoprostol given to 271 women was compared with non-identical placebo given 10 275.
Measure of collected blood loss equal 10 or grealer than 100000L was the primary
outcome. This sludy did report a sample size calcul:ation and computer generated random
a1localion. They found no difference in rotes of postpartum hemorrhage. 4.8% and 7%
respeclively, although they were al risk for type II error, as the rate of postpanum
hemorrhage in their control group W3S nO( as high as th3t estiffi3ted in their sample size
calculation. Shivering, with an overall incidence of 7.1% measured on the final 70
women enrolled, was nof a significant side effect.
Finally, Hofmcyr et al. published a comparison of oral misoprostoJ. 4ClOJ,lg with
non-identical placebo in 250 women per group (31). Measure of collected blood loss
equal to or greater than lOOOmL was the primary oUlcome. This study reponed a sample
size calculation and computer generated random allocation. They found no significant
difference in postpartum hemorrhage. but significantly less subsequent oll:ytocic use in
the misoprostol group. This trial was also at risk for type II erT(X" foc the same reason as
the previous trial. They found shivering to be more common in the misoprostot group.
with a rate of 19% versus S% in the placebo group. Thus. there still h:lS not been a well-
designed randomized comparison of oral misoprostol with a standard uterotonic for
prevention ofpostpanum hemorrhage.
In 1998. O'Brien et 01. reponed the usc of rectal misoprostol, I~g in 14
women. for the tremment of postpartum hemorrhage. Eligible women were those
clinically diagnosed with postpartum hemorrhage. unresponsive to oxytocin and
ergometrine. or ergometrine was contra-indicated. While waiting for carboprost
(Hemabate), the standard treaunent. to become available. misoprostol was given, In all 14
patients hemorrhage was controlled prior to the availability of carl>oprost (32).
"
2.4 Significance
MisoproslOl offers several advantages over the currently available uterotonics. II
requires no refrigeration or pI'O(ection from light. No sterile equipment is required for
adminislrntion. It is inellpensive. and has relatively few side effects. 1nese
characterislics make it ideal fOf use in developing coontries where tile incidence of
postpanum hemorrltage can be the highest. During preparation for this study a
prospective observational study was published using misoproslOl for prophyl3llis ag3.inst
postpartum hemorrhage in the third stage, in 237 patients (27). Their conclusions were
that the rates of poslpartum hemorrhage. need for further ollylocics, and length of the
third stage were decreased when compared with historical results of physiologic
management of the third slage and similar to those of Syntometrine@. 1bey also
concluded that side effects associated with misoprostol were less, and they fell that a
double blind, randomized, controlled trial was urgently needed.
If misoprostol can be shown to be effective in minimizing blood Joss in the third
stage of labour, in a low risk setting, further study of its use in treatment of postpartum
hemorrhage would be appropriate. If misoprostol is proven to be effective in the
prevention and treatment of postpartum hemorrhage, there is a potential to reduce
maternal mortality globlilly.
Of increasing importance in developed countries, where maternal mortality is low,
is the quality of the birth experience. This is evidenced by changes in birthing rooms to
reflect the more comfortable lltmosphere of a private room. with medical equipment
hidden out of eyesight until and if needed. Similarly, there has been a recent surge in the
popularity of midwifery in North America. In developed countries. women have become
"
powerful advocates on their own behalf to obtain these apparen! luxuries. In fhe medical
profession, where a physician is often concerned wilh preventing mortality. Ihe
importance to the patien! of these elemenrs of the birth experience can be underestimated.
The availability of an oral tablet. as an alternative 10 an intravenous injection for the
purpose of PPH prevenlion for women who have nol required an IV in labour. may be an
additional elemen! to improve the birth experience.
"
ChapteR" 3: l\1ETHODQLOGY
3.1 StandaR"d Management orthe Thin:!. Stage
In our center. !he standard management of the third stage depends upon the
preference of !he anending physician. However. there is relatively little variation. An
intravenous bolus of oxytocin immediately after delivery of the placenta is customary.
The dose is 5 or 10 unilS. Occasionally this will be given prior to delivery of the placenta
once delivery of the fetus' anterior shoulder is visualized. The advantage of this would
be to cause a uterine contraction, which would hasten the delivery of the placenta, shorten
the third stage, and therefore decrease blood loss. A theoretical disadvantage of this
practice is the question of whether this increases the risk of a retained placenta. which
prolongs the third stage. leading to increased risk of PPH (9). There are studies. which
demonstrnte each side of the argument, but the rna.jority of studies demonstrate no
increase in incidence of retained placenta (6,33,34). It remains the cum:nt practice of the
majority of physicians at our center to administer 5 units oxytocin after placental
delivery. The umbilical coni is clamped immeditl.tely after delivery and controlled cord
traction is applied after signs of placental separation occur.
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3.2_
The original intention of this study was 10 compare misoprostol to oxytocin with
frequency ofpostpanum hemorrhage as the primary outcome measure. A chart review of
50 nonnal vaginal deliveries revealed the rate of postpartum hemorrllage 10 be less than I
percen!. With this low incidence and a binhr:ue in our center of approximately 2400
deliveries per year, the study would nOI have been feasible. An ahemalive outcome
measure of a clinically significant blood loss. but less than 5OOmL. was chosen. A survey
of eight locally practicing obstetricians was conducted (Appendix B) to obtain a measure
of clinically significant difference in blood loss. reflected by a change in hematocrit,
between ueatment and control groups. It was decided lhal the infonnalion obtained from
this study, which was expected 10 demonslIate the safety and efficacy of misoprostol in
minimizing postpartum blood loss in a controlled setting of low risk palients. would be
valuable as preliminary work to support further investigation of misoprostol for PPH
prevention and lrealment.
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3.3 Primary Outcome Measure
When studying postpartum blood loss. l1leaSuring it accurately and objectively is
difficult Postpartum hemorrhage has classically been dcfinctl as clinically estimated
blood loss greater than 500mL within the first 24 hours of a vaginal delivery. It is well
documented that clinical judgment underestimates the actual blood lost by approximately
50 percent. However. meticulous collection of postpartum blood loss is tedious. and also
subject to error. ACOG has indicated thal a drop in hematocrit of 0.10 be used as a more
objective definition of postpartum hemorrhage (35).
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3.4 Sample Size Calculation
A chart review of fifty nonnal vaginal deliveries revealed an average drop in
hematocrit of 0.03 and a standard deviation of 0.03. The survey conducted or the locally
practicing obstetricians yielded a clinically significant drop in hematocrit of 0.042.
Selt=Cting drop in hematocrit as the primary outcome measure is particularly appropriate
to reduce bias in this study, as the study is not blinded. Oxytocin 5 or 10 units given
intravenously was chosen as the standard, as it is the customary uterotonic agent given, at
the discretion of the attending physician, al our center. The sample size was calculated
using a one-tailed a--o.05, ~=O.20, 1i=O.OI2, and 0=0.03, using the formula to compare
means of two independent groups (Figure 3.1). Given the advantages of oral misoprostol,
it would be considered an acceptable alternative if proven to be as good as, or better !han
oxytocin. Therefore, a one-tailed a was chosen 10 demonstrale that misoprosiol is as
good as or better than oxytocin in minimizing blood loss in the third stage or labour,
20
Figure 3.1: Sample size calculation
Figure3.la: Delta
Delta = clinically significant Hc!. drop - mean Hct. drop
= 0.042 - O-<XB
=0.012
Figure 3.lb: Sample size
N/group = 2l(Zalpha + Zbetal sigma2/delta2]
= 2«1.65 +0.84)2 (0.03)2/ (0.012)2]
=77.5
=78
21
3.5 Secondary Outcome Measures
Important secondary oUicome measures fell into one of a number of categories.
I. Other blood loss indicators:
EBL greater than 500mL
Clinically significant anemia (Hb. Less than lOOgfL)
Transfusion therapy
Hct. fall >0.10
It. Third stage variables related to postpartum blood loss·
Length of the third stage
Retained placenta
III. Other interventions for excessive blood loss:
a. Medical
Further oxytocin as intravenous bolus or infusion
Administration of carboprost
Administration of ergonovine
b. Surgical
Manual placental removal
Dilation and curettage
Laparotomy
Hysterectomy
22
IV. Side Effects:
Nausea
Vomiring
Pyrexia
v. Palienr Sarisfaclioo:
Modified Labor Agenlf)' Scale (Appendix C)
Postpartum fever was added as a secondary outcome based upon a report of
pyrexia with misoprostol use in this setting, published after the study had already
begun (27).
2J
3.6 Study Design
A prospeclive blinded randomized trial would be the oplimal study design 10
answer the research question being posed thaI is 10 best establish cause and effcct. An
assessment of the cost of placebo was obtained. An application for funding was
submiued 10 the Association of Professors in Obstetrics and Gynecology, but was
declined. The company manufacturing misoproslol had previously been approached
regarding the initially proposed third Slage sludy and had declined sponsorship.
Therefore, no funding for a placebo controlled trial could be found. Although the study
could not be blinded, il was felt that having an objective primary outcome measure would
reduce the polential bias. However, many of the secondary OUICOmes were subjeclive.
3.7 Subject Eligibility
Subjects under the age of 19 years old were excluded. as required by the elhics
commillee at our centre, Patients with risk factors for PPH were also excluded (i.e.
muhifelal gestation, hydramnios, HELLP syndrome. known coagulation abnormalilies,
grand multiparas (women ddivering their fifth child), women with a previous PPH,
placenta previa, cesarean delivery, precipitous labour (less than three hours),
chorioamnionilis, and women with anemia
(Hb.< 90 gIL). Augmentation with oxytocin in labour is a risk factor for PPH bec3use it
generally is associated with a prolonged labour. However. many studies investigating
PPH have found no increase in the incidence of PPH in this group of patients
(8,34,36,37). Induction with oxytocin is generally followed by continued augmentation
with oxytocin. Oxytocin augmentation in 13bour is such a common occurrence that
excluding this population of patients would affect the generalizability of the results.
Therefore. it was decided that it was reasonable not to exclude women based upon this
criterion. But bec3use oxytocin 3ugmentation in labour is generally considered a
predisposing factor for increased postpal1um blood loss. a pre-randomization
stratifiC.'ltion was conducted for paEients with this intervention. All patients who did not
meet exclusion criteria and presented in labour were considered eligible.
3.8 Study lnten'ention
1be dose of misoproslol was chosen before repons of misoproslol given for this
purpose had been published. Induction of labour wilh misoproslol had been carried out
in our center in a research selting. 1be dose for induction was .5O\.lg at a dosing interval
of four hours. There had been some concern regarding uterine hype£stimulation with Ihis
regimen. leading to investigation of optimal dose and dosing interval. which is currendy
being conducted. Second trimester terminations have also been investigated at our center
using misoprostol. Since hyperstimulation is nOl a concern in this selling and labour is
more difficult to induce, a higher dose of 200!lg is used and is effective. Based upon this
experience of the uterine stimulation obtained with these regimens, an artJitrary dose of
200JJ.g was chosen.
A maternal blood sample for hematocrit and hemoglobin was obtained prior to
delivery. the cu~om in our center. 1be woman was randomized to receive either
misoprostol ~g orally with delivery of the anterior shoulder. or pitocin five or ten
units (based on auending physician preference) intravenously after placental delivery. In
both groups controlled cord It3Ction was considered appropriate when signs of placent.al
separation were evident. After receiving misopfOSlOl, palients in the study group were
nOI treated differently with respect to management of the third stage of labour. If, in the
opinion of the allending physician, the particip::lOt experienced excessive blood loss, the
physician was free to intervene according to their customary management plan. including
administering intravenous oxytocin as a bolus or infusion. or further medications as
deemed necessary. WOlnen who received oxytocin in labour. customarily have an
26
infusion continued postpanum. This standard management was also carried out in lhe
study group. Women were then followed. as per routine, with regular visual assessment
of blood loss and palpation of uterine tone. by lhe anending nursing slaff. If a participam
experienced excessive blood loss Of" had a "boggy" uterus. a physician was noIified, and
look necessary measures after palienl assessmenl. A record was made of further aclions
required based on clinical estimation of excessive blood loss. A second blood sample for
maternal hemalOcrit and hemoglobin was obtained 24 hours (+1- 6 hours) poslpanum.
Subject satisfaction was assessed by a modified Labour Agentry Scale, administered
postpartum bUI prior 10 hospital discharge (Appendix C).
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3.9 Description or Siudy Institution
The study was conducted at the Grace General Hospital, SI. John's
Newfoundland. from October 13. 1997 to January 18, 1999. This center is the teniary
referral cemer for the province of Newfoundland and Labrador. as well as pans of
Quebec. The delivery rate is approximately 2400 per year. Both obstetricians and
general practitioners admit and care for patients. Obstetric/gynecology residents. family
practice residents. and medical and nursing students panicipate in patient care. Between
approximately 8am and 5pm consultants and general practitioners care for their own in-
patients. Family practice physicians arrange for "on call" coverage of patient care within
their practices. A single specialist obstetrician/gynecologist provides "on call" coverage
for their patients and family practice consults. A resident. intern. and medical student
also provide "on call" coverage. There are no independently practicing midwives in the
hospital. Nursing staff support patients in labour in the caseroom. as well as on the
obstetrical ward. in shifts. The patient population is predominantly Caucasian women.
No official data on the PPH rate is available. A chan review of 50 normal vaginal
deliveries revealed a rate of less than 1%.
3.10 Etbics and Consent
The sludy was approved by the Human lnve5ligation Commillee of Ille Facuhy of
Medicine. Memorial University of Newfoundland. and the hospital elhics board.
ObslelricianslgynecologislS and general prncIilioners performing deliveries al the Grace
General Hospital were COniacled in writing. The purpose and design of Ille study were
outlined and a copy of Ihe consenl fonn was included. No physicians refused 10 allow
(heir palients to be approached for recruitment
Consent was obtained by the altellding resident or staff physician, with 3
standnrdized consent form (Appendix D), upon paticni ndmission to the caseroom in
labour. This was obtained after Ihe patient and her partner, if available. hnd an
opportunity 10 review both the information sheel (Appendix E) and consenl fonn. The
study was also explained verbally and patients were encouraged to ask questions which
were answered to their satisfaction.
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3.J 1 Patient Recruitment
Eligible palients were identified upon admission to the caseroom. This was
generally done by the resident working in the caseroom during the day, the investigator,
or the "00 call" resident. Recognition of eligible palients by lhe nursing staff was also
very imponant, as the attending resident. busy with their regular work:. did nOl. always
remember to approach eligible patients for recruitment. In this instance, the nursing staff
would supply the patient with tl11 infom13.tion sheet to read until the resident or attending
physicitl11 were available to discuss the study with the patient.
The discussion included a summary of the background infonnation, a description
of the standard managemenr of the third slage and a description of the proposed sludy
intervention. Risks and benefits of panicipating were discussed. Patients were informed
of the fact thai they would receive an additional blood Icst if they chose 10 participate.
Patients were reassured that lheir participation was entirely voluntary, and that, should
they decline panicipation, their care would not be compromised in any way. Palients
were encouraged to discuss their thoughts privately wilh their panner, and 10 verbalize
any questions they had. If lhey appeared 10 undersland welt and were agreeable. lhey
were asked 10 sign the coosent fonn in the presence of lhe residenl or staff wilh whom
they had the discussion. who also signed the consent form.
Given the imponance of the team effort for patient recruitment and care during
the study, information sessions were held by the investigator with the attending
physicians. residenrs and nursing staff from time to lime. The objectives of the sludy
were discussed, as well as the therapeutic intervenrion and subsequenr managemenr (i.e.
thai it should nOI in any way be different) of the patient. As the study proceeded. this
JO
also provided an opportunity for suIT 10 communicate any lechnical difficullies
associated with impkmenling the siudy and a forum for discussion on how 10 overcollle
lhese difficulties. These ITleelings also served as posilive reinforcemenl for lhe
lremendous eITons of the siaff and maintained enlhusiasm fOf" the siudy.
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J.12 Randomization
Randomi1..lIion was perfonned by computer gener:lIed random numbers in
randomly a1lemaling blocks of four and six (Statisrix 4.1. Analytical Software.
Tallahassee. Florida). As previously mentioned. there was a pre-randomization
stralificalion for oXylocin use in labour. Cards nurted with either "Misoprosto!" or
"Oxytocin" were placed in sequentially numbered opaque and scaled. Each envel~
Ihen had a copy of the infomlation sheet. consent sht':et. modified Labour Agentry Sc3le
(38). and dala collection sheet attached by paper clip. The envelopes were Ihen placed
within file folders and placed in Ihe cascroom.
Once a patient had been idemified as being eligible. they were approached for
panicipalion. If they consemed. then immediately prior to delivery, the women were
allocated 10 sludy or conLroI group by opening the nexl envelope in the appropriate
stratum. which was perfonned by the allending resident, staff. or nu~. 1be COOlents of
the envelope and anachmenls were then placed in the p:uticipam's chart. A record was
kept of all women approached. If they declined or if they subsequently met exclusion
criteria prior 10 randomization, this was recorded. If lhey were randomized, lheir group
allocation was nOled. This list was checked on a daily basis and data from randomized
patients collected. The remaining envelopes were also checked daily to ensure adequate
supply and that no envelopes went missing.
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3.13 Data
lOe data was collected by reviewing the patienl chart and recording information
on !he data collection sheet (Appendix F). The Labour Agentry ScaJe was also collected
from the patient The <l3ta was then enlered inlo the computer database awaiting
statistical analysis following study complelion. This was pcrfooned with the same
computer program as the randomization, Stastistix 4.1. Entry of the data was callied out
by a research nurse. Regular discussions occurred between the nurse, investigator, and
one of the supervisors regarding problems with data entry (i.e. data missing on 24 hour
hematocrit. analyzing data on an intent to treat basis, etc.). No speculation on oulcomes
was discussed. A post hoc analysis of postpartum lemperature greater than or equal 10
37.5°C was perfonned. This data was obtained retrospectively.
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Chapter-4: RESULTS
Data were analyzed on an intent to treat basis by parametric (studenl's t test. chi-
square) and non-parametric statistics (Fisher exact. Mann Whitney U tests) using
Slatistix 4.1 (Analytical Software, Tallahassee, A). Significance of the primary outcome
was coosidered at P<O.05. The level of significance for all secondary all3lyses was
P<O.OOI (by Bonferroni correction).
During the sludy period 233 women were approached for enrollment. Forty
women declined participation and 193 gave consent. Of those consenting. 17 were
excluded because of cesan:an birth. An additional 3 consenting women were not
randomized due to precipitate delivery. One hundred and seventy-three women were
randomized, 88 in the oxytocin group and 85 in the misoprostol group. Data for the
primary outcome of change in hematocrit was available for 156 women. 80 in the
misoprostol group and 76 in the oxytocin group (Figure 4.1). Of the eighteen women
who have no data available on postpartum hematocrit change, none were diagnosed
clinically with postpartum hemontt.age or received transfusion therapy. Randomization
was effective as there were no significant differences between the two groups with regard
to maternal and neonatal demographic data (Tables 4.la and 4.1 b).
delivery He!.
Figure 4.1: Aow diagram of subject assignment
delivery He!.
Table4.1a.
Demographic Characteristics
Oxytocin Misoprostol P
n=76 n=80
Matemal age (y)Y 28.4(4.1) 27.6(4.7) 0.27*
Pari~ 0(0,1.0) 1.0(0,1.0) 0.8SIl
NulliparousY 38 40 1.00~
Antepartum Hct. 0.37(0.03) 0.37(0.03) 0.70·
(%PCV)'
Birthweight (g)Y 3569(530) 3517(459) 0.51·
l'Qata given as number or mean (standard deviation)
&Data given as median (25%, 75% quartiles)
'Student'sttest
~Chi·squared
llMann Whitney U lest
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Table4.1b.
Puerperal Characteristics
Oxytocin n=761 Misoprostol n=801
Intrapartum oxytocin 48 48 0.69~
Induction 22 14 0.09~
Augmentation 26 34 0.29~
Duration Stage I (min) 426(241) 386(230) 0.29"
Duration Stage II (min) 70(62) 68(63) 0.86"
Delivery 0.30~
NVD 59 62
Vacuum 10
Forceps 12
Episiotomy 0.69
Median
Mediolateral 18 21
Laceration 0.48'
lsi degree 12 17
2nd degree 29 24
3rd de9ree
Temp ~7.5°C in labor 17 23 0.75'
l'£>ata given as number or mean (standard deviation)
'Student'sttest
~Chi-squared
'Fisher exact test
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4.1 Primary and Se<:ondary Outcomes
11le mean drop in hemalocril 24 hours poslpartum. the primary OUlcome measure.
was nol significantly differenl between the IWO groups (Table 4.2). There were no
significanl differences in secondary oulcomes. including postpanum hemormage.
anemia. administration of Carboprosl or ergonovine for excessive bleeding. incidence of
transfusion, manual removal of the placenta. and postpar1urn dilation and cureltage. No
palients required laparolomy or hysterectomy. There was tl lrend toward more women in
the oxytocin group receiving addilional oxytocin (immvcnous bolus or infusion)(5In6)
compared with the misoprostol group (34/80XP=O.OO2). There was also a trend towards
a shorter third stage in the misoprostol groop. but this did not reach statistical
significance (P=O.095). There were no differences in nausea and vomiting between the
two groups (Table 4.3). There was a !rend loward a higher rate of poslpartum
temperature grealer than or equal 10 37.jOe in the misoproslol group. from data available.
bUI this did not reach stalistical significance (Table 4.4). There were no differences in the
modified l...abc:w Agentry ScaJes belwt:cn the two groups (by Mann Whitney U ICSI).
excepl for one question. More women in the misoprostol group agreed with the
slatement "I would prefer 10 have a medication in the foml of a pill ralher Ihan an
intravenous injection. at the time my baby is delivered." (P<O.OOOI. Mann Whitney U
lest).
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Table 4.2.
Data given as number or mean (standard deViation)
'Student'sttest
MChi-squared
'Fisher exact test
Postpartum Osts
Oxytocin n=761 Misoprostol n=801 P
Postpartum Hct.(PCV) 0.32(0.04) 0.33(0.04) 0.61"
Postpartum Het. Change (PCV) 0.048(0.036) 0.046(0.036) 0.82'
Estimated blood loss >SOOrnL 7 8 0.95-
Hb.<l00 (9/L) 22 19 0.43"
Duration stage III (min) 12.9(17.9) 9.1(8.3) 0.095'
Additional POStpartOOl oxytocin 51 34 0.002"
Postpartum carboprost 0.74
One dose 0 1
Two doses 1 0
Postpartum ergometrine 0 0 1.00
Bk>od transfusion 1 0 0.49
Manual placental removal 1 1 1.00
Postpartum D&C 2 0 0.24
,
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Table 4.3.
data given as number (%)
(lMann Whitney U test
Side Ellects
Oxytocin Misoprostol P
n=641 n=581
Nausea 0.37'l
Mild 8(12.5) 15(25.9)
Moderate 3(4.7) 1(1.7)
Vomiting 0.81°
1·2 episodes 5(7.8) 5(8.6)
3-4 episodes 2(3.1) 0(0)
>4 episodes 0(0) 0(0)
,
Table 4.4.
Data given as numberlsample{%)
·Chi-squaredtes{
~isherexacttest
rremperature ~7.5°C
OxytocinT Misoprostorr p
1hr. postpartum 6/24(25.0) 17134(50.0) 0.055-
4hr. postpartum 11/53(20.6) 17/53(32.1) 0.19"
24hr.postpartum 2/71(2.6) 5/76(6.6) 0.44
,
Chapter 5: DISCUSSION
5.1 Discussion or Results
In this study, there were no significant differences between groups in any blood
loss parameters, including change in hematocrit. the primary outcome measure. Except
for a trend towards an increase in subsequent postpartum oxytocin use in the oxytocin
group. there were no differences in further interventions for excessive blood loss. As the
study was not blinded. this intervention was subject to bias. There was also a lrend
towards a shorter third stage in the misoprostol group, ahhough it did not reach statistical
significance. Side effects of nausea and vomiting were not different between the groups.
We began looking at poSlpartum temperoture part way through the study, based
upon a report of pyrexia as a side effect of misoproslol (28). Prostaglandin E2 is an
ecosaooid known to have a causative role in initiating and suslaining pyrogen induced
fever. It is known to act 00 the pre-opric area of the anterior hypothalamus (39).
Prostaglandin E2 also acts at Olher sites in the brain, bUI action at these Olher locations is
not well understood (39). The exact mechanism whereby prostaglandin E2 causes
lemperature elevation is unknown (39). AniITl:l.I research is ongoing in this area.
Misoprostol is known to act as an agonist on prostaglandin E receplors EPI and EP2 in
vivo in the human uterus, as does prostaglandin E2 (26). It is plausible thai misoprostol
could cause temperature elevation via the same mechanism as prostaglandin E2.
The information on temperature was collected relrospectively on a smaller
number of patients, making it impossible to draw definite conclusions based upon this
dara. Temperatures were similar, except for a trend towards a higher rate of one-hour
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postpanum temper:lIure gre:uer than or equal to 37.5°C. The highest poslp31tum
temperatures recorded were in the misoprostol group. Two women had temperatures
greater than 39"C. These were 39.4°C at twO hours and 39.2°C at one hour. The first
......oman had an intrapartum temperature of 38.4°C approximately one hour priOf" to
delivery with membranes ruptured greater than 18 hours. However. her temperature then
rose to 39.4°C after administration of misoproslol. She was treated with intravenous
antibiotics for 24 hours. Her temperature dropped to 38.5°C at three hours and 37.5°C at
24 hours. Thus, her fever was likely due to both infection and misoprostol. The second
woman was afebrile at the onset of labour and had no further temperatures recorded until
the one-hour measurement of 39.2°C. However, her labour progressed well with
membranes ruptured for just three hours. At two hours postpartum. her temperature had
fallen to 38.2°C and to 37.4°C at 17 hours postpartum. She was treated with intravenous
antibiotics for 24 hours and was disch~ on oral antibiotics. It is likely that this
temperature elevation was a result of the misoprostol. There were two women. also in
the misoprostol group, with temperatures greater than 38.5°C. These were 38.6°C and
38.7°C. both at one hour postpartum. The first woman was afebrile during labour but h3d
no temperature recorded from approxim:lIely six hours before delivery until :lbout one
hour postpartum. She had rupture of membranes for eight and a half hours. Her
temperature elevation had resolved within six hours. Although she was given
intravenous antibiotics, because of the rapid resolution of the fever. it was likely due to
the misoprostol. The highest temperature recorded for the second woman was 39.3°C.
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intrnpartum afler ruplure of membranes for six and a half hours. She was lIeated with
inlravenous anlibiOlics inlrapaltum and one hour al1.er delivery her temperature dropped
to 38.7"C and 37.5°C six hours postpartum. Infection was !he likely cause of this
woman's temperature elevation. Temperature elevation should not cause serious
consequences unless supra physiologic (greater Ihan 41"C1 105°f) or prolonged (40).
Young women withoul significant cardiovascular or pulmonary disease should tolernte
trnnsient physiologic tempernture elevation well. However, there are potentially adv~rse
side effects from antibiotic therapy, which may not be necessary for transient pyrexia in
the absence of symploms or other signs of infection.
Previously, three of the misoproslol lhird stage trials reported shivering as a
remarkable side effect (27, 28, 31). Two of the lrials did not ask aboul shivering (29. 32)
or no difference was found between groups (30). One of these studies also found a 0.5°C
lemperature elevation afler misoprostol adminiSlrntion 10 be S1astically significanl (28).
To del.ermine a dose related side effect profile with respedto lemperature and
shivering administration of 600J.tg and 400!J.g of misoproslol was compared wilh
oxytocin (41). The relative risk. of shivering with 600J.tg of misoproslOl was 2.3 (CI 1.5-
5.5) when compared with oxylocin. For misoprostol 4()(\lg compared with oxytocin. lhe
relative risk was 1.54 but the CI was 0.96-2.44. With regard to temperature elevation, the
relative risk of temperature gl'e<ller than 38°C was 3.7 (el 1.3-10.9) versus 400~g of
misoprostol and 2.5 (CI 1.0-3.6) versus oxylocin. With 40011& of misoprostol an
increased risk. of temperalUre elevation was nOI demonStraied.
With resptClto patient satisfaction. the only significant difference found between
groups was that a greater proportion of women preferred to have their medication in the
form of a tablet. rather than an injection. This question was one of sevcral questions
added to the standard Labour Agentry Scale. The labour Agentry Scale was designed to
measure a woman's sense of control during labour and delivery, as a perception of
control was demonstrated to increase tolerance of higher levels of pain and improve
functioning on various tasks (38). A woman's perception of control was also correlated
with an improved birth experience (38). Thus those women who were given an oral
tablet in the third Slage would prefer this option again.
5.2 Problems
Recruiting patients in labour is difficult. MOf"e p.:atients declined panicipation than
expected. For these reasons. recruitment for this study was much slower than anticipated.
The time differential between consent and randomiZ3lion caused many problems.
Randomization had 10 occur just prior to delivery, to ensure Ihe patient was eligible to
participate. Some patients who consentcd were never randomized, as the time just prior
to delivery is very busy and opening randomization envelopes was occasionally
forgotten. Ordering the 24-hour postpartum hematocrit nnd hemoglobin was at times
forgotten. Subsequently, twice daily the investigator or resem'ch nurse checked the chans
of new participants 10 ensure the 24 hour hematocrit was ordered. Patients receiving the
wrong medication also occulTed. Administration of oxytocin is the routine; occasionally
this was given instead of misoprostol, although data were analyzed on an intent to treat
basis. Administration of misoprostol with the anterior shoulder is difficult, and often
administration was a short rime after this. In summary. the study required the
coordinated effons of many personnel.
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5.3 Slrtngths and Weaknesses
5.3.1 Validity
The assignmenl of ptatients to the treatmenl groups was randomized. Tables la
and Ib illustrated that the groups did appear to be demographically similar ilt the start of
the trial. Although eighteen women did not have data available on postpartum hematocrit
change. they were not considered entirely lost to follow up as it is known that none of
them had transfusion therapy or a clinical diagnosis of postpartum hemorrllage. The
palient data was analyzed on an intent to m:at basis. preserving the benefits of the
randomization. Recruitment was continued until Het. data was available for 76 women in
the oxytocin group and 80 women in the misoprostol group.
This was not a blinded study, for fellSons previously discussed. This does
introduce possible bias. Given the primary outcome measure was objective and the
personnel involved with measuring hematocrit were blind to patient group assignment.
this billS should be reduec:d. However. a number of the secondary outcomes were not
objective measurements made by personnel unaware of group assignment.. Therefore.
inferences made based upon this data must be viewed with caution. as the possibility of
coinlervenlion does exist.
Administration of 5 units of intravenous oxytocin postpartum is the most common
practice at our centre. A small number of attending obstetricians prefers 10 units of
oxytocin. We did not restrict the standard treatment 10 5 units to prevent non-
panicipation of these obstetricians in the study. There may be better efficacy of the 10
unit dose.
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Allhough nuid retention due to postpanum oxytocin infusion may affect Het.. the
administmtion of postpartum oxytocin was not significantly different between groups
..
5.3.2 Applicability
TIle study results are potentially applicable to a very select population. TIle study
sample was taken from a homogenous population of p:ltiems at low risk of postpanum
hefT1OrThage. All clinically relevant OUlcomes were considered wilh the possible
exception of pyrexia, which was added as a secondary ootcome once its significance was
appreciated. The sample size was not large enough 10 address significant, but rare
outcomes, such as laparotomy and hysterectomy. However, there is no queslion that the
administration of misoproslol instead of oxytocin is both feasible and beneficial 10
postpartum patients.
"
5.4 Conclusions
Misoprostol is no less effective than bolus intl'3venous oxytocin in control of
postp3rtUm blood loss in low risk women. with minimal side effects. A blinded
randomized controlled trial with objective measurement of the incidence of postpanum
hemon1lage as the primary outcome would be mon: definitive. This could be
accomplished in a multi-center trial or in a developing Country, where the incidence of
postpartum hemon1lage and the birthrate are higher. Investigation of misoprostol use in
the third stage should include regular measuremcnts of intrapartum and postpanum
temperature to assess the paltcm of return to nonnaltcmpcralure and to help differentiate
pyrex.ia caused by misoprosto! from pyrex.ia due to infection. Investigation of opcimal
oral dose. comparison with rectal misoprostol and prophylactic use in high-risk patients
are areas for funher study. Ultimately. misoprostol should be in"estigated for the
treatment of postpartum helTlOfThage. where it could be revolutionary in reducing
maternal mortality in developing counaies.
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APPENDIX A
Risk Factors for PPH
I. Increased risk of uterine atony
a. Uterine overdistention
i. Polyhydramnios
ii. Multiple gestation
iii-Macrosomia
b. Prolonged labour
i. Cesarean delivery
ii. Operative vaginal delivery
c. Precipitate labour
d. Chorioamnionitis
e. Medications
i. Tocolytic agents
ii. Halogenated anesthetic agents
f. High parity
II. Increased risk of genital lract lacerations
il. Operative delivery
i. Forceps or vacuum extraction
ii. Cesarean delivery
b. Episiotomy
c. Macrosomia
d. Prolonged or precipitate delivery
III. Increased risk ofulerine rupture
a. Previousulerinesurgery
i. Cesarean delivery
ii. Qther utcrine surgery
b.Olhcrprocedures
i. Podalic version
ii. Breech extraction
iii. Midforceps
c. ObSlnlCled labour
d. Abnonnal felal presentation
c. Highparity
"
APPENDIX B
MISOPROSTOL VS. OXYTOCIN IN THE THIRD STAGE OF LABOUR IN THE
PREVENTION OF POSTPARTUM HEMORRHAGE.
My intent is to sludy misoprostol given with delivery oflhe anterior shoulder in
comparison to the standard, in our center. of IV oxytocin arrer delivery of the placenta.
for the prevention of excessive postpartum blood loss. In a chart review of patients
delivering in our center. the average drop in hematocrit, in women experiencing vaginal
deliveries, isO.Q3.
1l\e benefits of oml misoprostol over oxytocin would inelude patient acceptance
of an oral medication instead of an IV injection. decre:tSCd nursing rime required to
prepare and administer the medication. and decreased cost as no sterile syringe and
needle required in administmtion.
What increase in postpanum blood loss (measured as a drop in hematocrit) would
you accept in the misoprostol group to justify its use instead of oxytocin in your patients?
( )O.OI-o.Q3
( ) 0.03-0.06
( )O.06·'H)9
"
( )other _
"
APPENDIXC
LAROIIR AGENTRY SCALE'
I. I felt compelent.
AGREE
2. I was dealing Wilh labour.
AGREE
3. Everything made sense.
AGREE
4. I felt very responsible.
AGREE
DISAGREE
DISAGREE
DISAGREE
DISAGREE
..
5. I felt incompelenl and like I was going 10 pieces.
AGREE
6. I fell secure.
AGREE
7. I fehincapable.
AGREE
8. I experienced a sense of greal anxiely.
AGREE
9. I felt adequate.
AGREE
DISAGREE
DISAGREE
DISAGREE
DISAGREE
DISAGREE
"
10. 1felt open and receptive.
AGREE
11. 1felt good about my beh::lviOf" during labour.
AGREE
12. I fc1r powerless.
AGREE
13. I experienced a sense of being with others who care.
AGREE
DISAGREE
DISAGREE
DISAGREE
DISAGREE
14. Ididn'l know what 10 expect fromooe momcnllO me next.
AGREE DISAGREE
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15. I experienced complete awareness ofe\'erything thai was happening.
AGREE
16. Everything seemed unclear and unreal.
AGREE
17. [felt relaxed.
AGREE
18. I experienced a sense of conflici.
AGREE
19. [fell fearful.
AGREE
DISAGREE
DISAGREE
DISAGREE
DISAGREE
DISAGREE
OJ
20. I had a sense of nOI being in conlrol.
AGREE
21. I fell important.
AGREE
22. Everylhing seemed wrong.
AGREE
23. (felt viClorioos
AGREE
24. (experienced a sense of active striving.
AGREE
DISAGREE
DISAGREE
DISAGREE
DISAGREE
DISAGREE
..
25. I had a feeling of conslriction and ofbcing confined.
AGREE
26. I felt awkward.
AGREE
DISAGREE
DISAGREE
27. Someone or something else was in charge of my labour.
AGREE
28. I experienced a sense of success.
AGREE
29. I had a sense of perspective on whal was happening.
AGREE
DISAGREE
DISAGREE
DISAGREE
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30. I received explanation regarding the safety and effectiveness of misoproslol.
AGREE DISAGREE
31. I would recommend the medication I received to a friend if she was having a
baby.
AGREE DISAGREE
32. If I have another delivery. I would be willing to panicip:ue in II similar
research study.
AGREE DISAGREE
33. I would prefer to have 8 medication in the form of a pill, rather than an
iOlravenous injeclion, at the time my baby is delivered.
AGREE
34. I experienced nausea after delivery of the baby.
ollld moderate
DISAGREE
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35. I vomited after delivery of the baby.
1+2 limes_ 3-4 times_ more than 4 tiRlCS_
Commencs:
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APPE!''OIXD
CONSENT FORM
MISOPROsroL VS. OXYTOCIN TO a.tlNL\UZE BLOOD LOSS L"'I THE THJRD
STAGE OF LABOUR.
INVESTIGATORS:
Dr. K. Baj:mk. Dr. J. Harnett. Dr. J. Crane, Dr. D. Young
DESCRIPTION AND BACKGROUND INI-URMAnON:
You are being asked to participate in a research study evaluating two different
medications given to minimize blood loss aflerdelivery. Usually, after a baby is born,
the mother is given an injection of a medication to help her uterus contract and thereby
minimize blood loss. AI our centre, the medication used is oxytocin, as an intravenous
injection, once the afterbinh has been delivered. Recently, a medication thai can be taken
by mouth, called misoprostol. has been given to a group of women. instead of the usual
medication. to sec ifit would also minimize blood loss.
In this study, we would like to compare blood loss in women given misoproslol
by mouth versus women given an injection of oXYlocin.
FORESEEABLE RISKS, DISCOMFORTS, OR INCONVENIENCES:
There will be an additional blood test taken approximately 24 hours after delivery
of your baby. You will be askcd to fill oul a satisfaction questionnaire before you leave
Ihc hospital. If the misoprostol is not effective, you may be givcn additional medicalions
10 minimize funher blood loss. These medications are givcn 10 decrease your risk of
eJlcessive blood loss after delivery.
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SIDE EFFECTS:
Possible side effects or misoprostol include nausea. vomiting and dilll'l'hea.
STUDY DESIGN:
If you choose to enter this study, you will be assigned at random (as irby the nip
of a coin) to one of two groups. One group will receive misoprostol. by mouth. and the
other group will be given an intravenous injection of oxytocin, immediately after the
baby has delivered. You will have a blood s:unple taken in 3pproxim3tely 24 hours to
estimate the amoum or blood loss you have had. Thcn your chart will be reviewed. by
the investigator. to retrieve the information required. You will remain under the care of
your own physici3n.
ALTERNATIVE TREATMENT:
If you chose not to emer the study, you will be given the usual treatment of
intravenous oxytocin immediately after delivery of your baby.
VOLUNTARY PARTICIPATION:
You may freely decide 001 to panicip:ue. or to withdraw from the Study at any
time, without affecting your norm:tl care. You should have discussed the information
provided with your physician and helshe should have answered any questions you have
regarding your care or treatment.
CONFIDENTIALITY AND ACCESS TO MEDICAL RECORDS:
You understand that records concerning your labour, delivery and hospital stay
will be reviewed, by the investigators or study nurse 3nd you give pennission for this.
"
No records bearing your name will be provided to anyone other than the investigators in
this study. You will not be identified in any publications in any manner.
Your signature on this form indicates lhat you have understood to your
satisfaction the information regarding your panicipation in the research project and that
you agree to participate 3S.ll subject. 10 no way does Ihis waive your legal rights. nor
release lhe investigators. sponson, or involved institutions from their legal and
professional responsibilities
The investigators will be .lIvailable should you have any problems or questions
regarding the study.
Patient Signature:
Witness Signature:
Investigator Signature:
Date:
Date:
Dale:
APPENDIX E
PADENT Ii''f"0RMADON SHEET
J\.USOPROSTOL VS. OXYTOCrN TO MINIMIZE BLOOD LOSS IN THE TIllRD
STAGE OF LABOUR.
INVESTIGATORS:
Dr. K. Bajuk. Dr. J. Crane.
DESCRlPTlON AND BACKGROUND INFORMATION:
You are being asked to panicipate in a research study evaluating IWO different
medicalions givcn to minimize blood loss afterdclivcry. Usually. after a baby is born,
the mother is given an injection of a medication to help her uterus contraci and thereby
minimize blood loss. Al our centre, the medication used is oXylocin. as an intravenous
injeclion. once the afterl>irth has been delivered. Recendy, a medication mal can be uken
by mouth. called misoprostol. has been given 10 a group of women. inSlcad oflhe usual
medication. 10 see ifit would also minimize blood loss. In lhal study. the invcsligalors
concluded thallhe nUnDer of women with excessive blood loss. after delivery, in those
given the medication by mouth. was similar to the number of women who usually have
excessive blood loss Ihal are given the siandard medicntion (an intramuscular injection.
similar to oxytocin).
In Ihis study, we would like to see if the medic(llion given by mouth, misoproslol,
is effeclive in minimizing blood loss, as compared wilh oXylocin.
FORESEEABLE RISKS, DISCOMFORTS. OR INCONVENIENCES:
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There will be an addilional blood lesT taken approximately 24 hours afler delivery
of your baby. You will be asked 10 fiU OUI a S3tisfocTion questionnaire before you kave
the hospila1. If the misoprostol is not effeclive, you may be given additional medications
10 help prevent excessive blood loss.
SIDE EFFECTS:
Possible side effects of misoproslol include nausea. vomiling and diarrhea.
STUDY DESIGN:
If you choose to enter this study, you will be assigned at random (as ifby the nip
of a coin) to one of two groups. One group will receive misoprostol. by mouth. and the
other group will be given an intravenous injeclion of oxytocin. immediately after lhe
baby has delivered. You will have a blood sampk taken in approximately 24 hours 10
estimate the amount of blood loss you have had. lben your chart will be R:viewed, by
the investigator. 10 R:lrieve the informalion required. You will R:main under the care of
your own physician.
ALTERNATIVE TREATMENT:
If you chose 00110 enter the study, you will be given the usual treatmenlof
intrnvenous oxytocin immediately after delivery of your baby.
VOLUNTARY PARTICIPATION:
You may freely decide not to panicipate. or to wilhdraw from the study al any
time, without affecting your normal care. You should hove discussed the infonnation
provided with your physician and helshe should hove answered any questions you hove
R:gording your care or treatment.
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CONFIDENTIALITY AND ACCESS TO MEDICAL RECORDS:
You understand tMt records concerning your labour. delivery and hospital stay
will be reviewed. by the investigators or srudy nurse and you give permission for this.
No records bearing your name will be provided to anyone other than the investigators in
this study. You will nOI be identified in any publications in any manner.
Your signature on the consent form indicates that you Mve understood to your
satisfaction the infomlation regarding your participation in the research project and that
you agree to panicip<tte as a subject. [n no way does this waive your legal rights, nor
release the investigators. sponsors. or involved institutions from their legal and
professional responsibilities.
The investigators will be available should you have any problems or questions
regarding the study.
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APPENDIX F
Chart # :
Group
Ag'
Gravidity
Parity
Oxytocin: () yes ( ) no
induction ( )
i) sian time
ji)deliverylime
augmentation ( )
i) slaltlime
ii) delivery time
Pre-Delivery Hct.
Post-Delivery Hct.
Change In Hct.
Further Administration of: (specify amount and number of doses)
OXYlOcin ( )
i) bolus (
ii) infusion (
Ergot ( )
Hemabate (
Other ( ) _
Clinical dx of pph ( ) yes ( ) no
Estimated blood loss cc
Operative Intervention ( ) yes ( ) no
manual placental removal (
d&c ( )
laparotomy (
hysterectomy ( )
Transfusion ( ) yes ( ) no
Type of Delivery
NVD ( )
Vacuum (
• Indication
• NRA-fRT (
• FTP ( )
Forceps ( )
• Indication
• NRFHRT (
• I-IP (
Perineal Trauma
Laceration I"degree ( ) 2""degree ( ) 3"'degree ( ) 4thdegree ( )
Epsiolomy ( )
Weight of Infant~
Length of Labour
• IS/stage __nUn
• 2nd stage__min
• 3nJ stage __min
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